FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Innoviva, Inc. INVA

Mixed   broader-coverage candidate · Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes s

On FrontierLab's discovery record since 2026-06-24 (14 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-11), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)19.8%
Gross margin73.1%
Gross profits / assets0.19
Rule of 4056.5
Net margin36.7%
Cash runway (months)—
PEG—
Price / sales3.4

Quality checklist

Fundamentals — snapshot as of 2026-09-11

StageEstablished
Share issuance (YoY)-13.1% · buying back shares
Moat—
TAM—
P/E (trailing)5
EPS (trailing)$4.10
Burn multiple—
Gross-margin trend (pts)-17
Cash / assets0.34
Net debt / EBITDA-0.4
Statements as ofQ2 FY2026 · filed 2026-08-05

Momentum context — a snapshot from 2026-09-11, not current

Price at surface$20.62 (as of 2026-09-11)
52-week range$16.52 – $25.15
% off 52-wk high-18%
RSI (14)40
Relative volume1.3×

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-11 (end-of-day). How grades are computed →